Medically induced gingival hyperplasia.
Gingival hyperplasia or gingival overgrowth is a common occurrence in patients taking phenytoin, cyclosporine, or calcium channel blockers. Speech, mastication, tooth eruption, and aesthetics may be altered. Controlling the inflammatory component through an appropriate oral hygiene program may benefit the patient by limiting the severity of the gingival overgrowth. In patients in whom gingival overgrowth is present or may be anticipated, recognition of this condition and referral to a general dentist or periodontist are appropriate steps to management. The physician's awareness of the potential for development of overgrowth and the dental practitioner's role in attempting to prevent or minimize this problem are important aspects. In this article, we discuss the medications associated with gingival hyperplasia and describe appropriate recommendations.
Meraw
S J
SJ
Department of Dental Specialties, Mayo Clinic Rochester, MN 55905, USA.
Sheridan
P J
PJ
D000927:Anticonvulsants / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects*; D005885:Gingival Hyperplasia / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D010672:Phenytoin / Q000009:adverse effects*
D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D010672:Phenytoin; D016572:Cyclosporine